Inflammation in sickle cell disease

Nicola Conran, John D Belcher

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

The primary β-globin gene mutation that causes sickle cell disease (SCD) has significant pathophysiological consequences that result in hemolytic events and the induction of the inflammatory processes that ultimately lead to vaso-occlusion. In addition to their role in the initiation of the acute painful vaso-occlusive episodes that are characteristic of SCD, inflammatory processes are also key components of many of the complications of the disease including autosplenectomy, acute chest syndrome, pulmonary hypertension, leg ulcers, nephropathy and stroke. We, herein, discuss the events that trigger inflammation in the disease, as well as the mechanisms, inflammatory molecules and cells that propagate these inflammatory processes. Given the central role that inflammation plays in SCD pathophysiology, many of the therapeutic approaches currently under pre-clinical and clinical development for the treatment of SCD endeavor to counter aspects or specific molecules of these inflammatory processes and it is possible that, in the future, we will see anti-inflammatory drugs being used either together with, or in place of, hydroxyurea in those SCD patients for whom hematopoietic stem cell transplants and evolving gene therapies are not a viable option.

Original languageEnglish (US)
Pages (from-to)263-299
Number of pages37
JournalClinical Hemorheology and Microcirculation
Volume68
Issue number2-3
DOIs
StatePublished - Jan 1 2018

Fingerprint

Sickle Cell Anemia
Inflammation
Acute Chest Syndrome
Leg Ulcer
Hydroxyurea
Globins
Hematopoietic Stem Cells
Pulmonary Hypertension
Genetic Therapy
Anti-Inflammatory Agents
Stroke
Transplants
Mutation
Therapeutics
Pharmaceutical Preparations
Genes

Keywords

  • Cytokine
  • endothelium
  • hemolysis
  • hydroxyurea
  • vaso-occlusion

PubMed: MeSH publication types

  • Journal Article

Cite this

Inflammation in sickle cell disease. / Conran, Nicola; Belcher, John D.

In: Clinical Hemorheology and Microcirculation, Vol. 68, No. 2-3, 01.01.2018, p. 263-299.

Research output: Contribution to journalArticle

@article{c492b6a2bf304683a02f1e883e4d4ba6,
title = "Inflammation in sickle cell disease",
abstract = "The primary β-globin gene mutation that causes sickle cell disease (SCD) has significant pathophysiological consequences that result in hemolytic events and the induction of the inflammatory processes that ultimately lead to vaso-occlusion. In addition to their role in the initiation of the acute painful vaso-occlusive episodes that are characteristic of SCD, inflammatory processes are also key components of many of the complications of the disease including autosplenectomy, acute chest syndrome, pulmonary hypertension, leg ulcers, nephropathy and stroke. We, herein, discuss the events that trigger inflammation in the disease, as well as the mechanisms, inflammatory molecules and cells that propagate these inflammatory processes. Given the central role that inflammation plays in SCD pathophysiology, many of the therapeutic approaches currently under pre-clinical and clinical development for the treatment of SCD endeavor to counter aspects or specific molecules of these inflammatory processes and it is possible that, in the future, we will see anti-inflammatory drugs being used either together with, or in place of, hydroxyurea in those SCD patients for whom hematopoietic stem cell transplants and evolving gene therapies are not a viable option.",
keywords = "Cytokine, endothelium, hemolysis, hydroxyurea, vaso-occlusion",
author = "Nicola Conran and Belcher, {John D}",
year = "2018",
month = "1",
day = "1",
doi = "10.3233/CH-189012",
language = "English (US)",
volume = "68",
pages = "263--299",
journal = "Clinical Hemorheology and Microcirculation",
issn = "1386-0291",
publisher = "IOS Press",
number = "2-3",

}

TY - JOUR

T1 - Inflammation in sickle cell disease

AU - Conran, Nicola

AU - Belcher, John D

PY - 2018/1/1

Y1 - 2018/1/1

N2 - The primary β-globin gene mutation that causes sickle cell disease (SCD) has significant pathophysiological consequences that result in hemolytic events and the induction of the inflammatory processes that ultimately lead to vaso-occlusion. In addition to their role in the initiation of the acute painful vaso-occlusive episodes that are characteristic of SCD, inflammatory processes are also key components of many of the complications of the disease including autosplenectomy, acute chest syndrome, pulmonary hypertension, leg ulcers, nephropathy and stroke. We, herein, discuss the events that trigger inflammation in the disease, as well as the mechanisms, inflammatory molecules and cells that propagate these inflammatory processes. Given the central role that inflammation plays in SCD pathophysiology, many of the therapeutic approaches currently under pre-clinical and clinical development for the treatment of SCD endeavor to counter aspects or specific molecules of these inflammatory processes and it is possible that, in the future, we will see anti-inflammatory drugs being used either together with, or in place of, hydroxyurea in those SCD patients for whom hematopoietic stem cell transplants and evolving gene therapies are not a viable option.

AB - The primary β-globin gene mutation that causes sickle cell disease (SCD) has significant pathophysiological consequences that result in hemolytic events and the induction of the inflammatory processes that ultimately lead to vaso-occlusion. In addition to their role in the initiation of the acute painful vaso-occlusive episodes that are characteristic of SCD, inflammatory processes are also key components of many of the complications of the disease including autosplenectomy, acute chest syndrome, pulmonary hypertension, leg ulcers, nephropathy and stroke. We, herein, discuss the events that trigger inflammation in the disease, as well as the mechanisms, inflammatory molecules and cells that propagate these inflammatory processes. Given the central role that inflammation plays in SCD pathophysiology, many of the therapeutic approaches currently under pre-clinical and clinical development for the treatment of SCD endeavor to counter aspects or specific molecules of these inflammatory processes and it is possible that, in the future, we will see anti-inflammatory drugs being used either together with, or in place of, hydroxyurea in those SCD patients for whom hematopoietic stem cell transplants and evolving gene therapies are not a viable option.

KW - Cytokine

KW - endothelium

KW - hemolysis

KW - hydroxyurea

KW - vaso-occlusion

UR - http://www.scopus.com/inward/record.url?scp=85047755924&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85047755924&partnerID=8YFLogxK

U2 - 10.3233/CH-189012

DO - 10.3233/CH-189012

M3 - Article

C2 - 29614637

AN - SCOPUS:85047755924

VL - 68

SP - 263

EP - 299

JO - Clinical Hemorheology and Microcirculation

JF - Clinical Hemorheology and Microcirculation

SN - 1386-0291

IS - 2-3

ER -